Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients : vimarsana.com

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United Kingdom , Glasgow , Glasgow City , Scotland , Avinash Desai , Actimaba National Cancer Institute , Exchange Commission , European Bone Marrow Transplant Society , Actinium Pharmaceuticals Inc , Actinium Pharmaceuticals , Antibody Radiation Conjugates , Complete Remission , Overcomes High Risk , Scottish Event Campus , Chief Medical Officer , North African , Annual Meeting , National Cancer Institute ,